Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 1040-1044, 2006. First published March 30, 2006; 10.1373/clinchem.2005.063925
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 063925.Suppl Data Table 1
Right arrow All Versions of this Article:
clinchem.2005.063925v1
52/6/1040    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Endler, G.
Right arrow Articles by Pabinger, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Endler, G.
Right arrow Articles by Pabinger, I.
Related Collections
Right arrow Hemostasis and Thrombosis
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2006;52:1040-1044.)
© 2006 American Association for Clinical Chemistry, Inc.

Hemostasis and Thrombosis

Anti-Cardiolipin Antibodies and Overall Survival in a Large Cohort: Preliminary Report

Georg Endler1,2, Claudia Marsik1,2, Bernd Jilma2, Thomas Schickbauer1, Rainer Vormittag3, Oswald Wagner1, Christine Mannhalter1,2, Helmut Rumpold1,a and Ingrid Pabinger3

1 Institute of Medical and Chemical Laboratory Diagnostics, 2 Department of Clinical Pharmacology, Division of Haematology and Immunology, and 3 Department of Internal Medicine I, Division of Haemostaseology, Medical University of Vienna, Vienna, Austria.

aAddress correspondence to this author at: Clinical Institute of Medical and Chemical Laboratory Diagnostics, AKH-Wien Währinger Gürtel 18-20, 1090 Wien, Austria. Fax 43-1-40400-5389; e-mail helmut.rumpold{at}meduniwien.ac.at.

Background: Anti-cardiolipin antibodies have been associated with both arterial and venous thrombosis, but their overall impact on all-cause or vascular mortality is unknown. In this study, we evaluated the influence of anti-cardiolipin antibodies on all-cause and vascular mortality.

Methods: All individuals who fulfilled the inclusion criteria (completeness of data, no admission from an intensive care unit, unique identification with name and date of birth) and whose anti-cardiolipin antibodies were measured between October 2002 and February 2004 were included in this study (n = 4756; 64% female; median age, 46 years). Death/survival and cause of death were obtained from the Austrian Death Registry. The median observation period was 1.5 years, and the study comprised 7189 person-years.

Results: During the study period, 184 patients (3.9%) died. There were no associations between either anti-cardiolipin IgM or IgG antibodies and both vascular death and noncancer mortality as outcome variables in a Cox regression analysis adjusted for age and sex. In contrast, the risk of cancer-related mortality was increased 2.6-fold.

Conclusions: Anti-cardiolipin antibodies are associated with cancer mortality, likely as an epiphenomenon of malignancy, but they are not predictive of vascular mortality or noncancer mortality. Hence, although a clear association between anti-cardiolipin antibodies and (mostly nonfatal) vascular events has been described in the literature, our data indicate that this finding is not necessarily associated with an increase in vascular mortality.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.